StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie synagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M)

Form 10-Q / 10-K Segment Note

Latest, Q1 2020
270
Period ended Mar 31, 2020
Change on a year earlier
-5.9%
287 in Q1 2019
History
13 quarters
Since Q1 2017
Sources
8
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSynagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M)Year on yearSource
Q1 2020Mar 31, 2020270-5.9%Form 10-Q (filed 2020-05-08) ↗
Q4 2019Dec 31, 2019261-1.1%Form 10-K (filed 2020-02-21) ↗
Q3 2019Sep 30, 2019132+36.1%Form 10-Q (filed 2019-11-06) ↗
Q2 2019Jun 30, 201938-13.6%Form 10-Q (filed 2019-08-05) ↗
Q1 2019Mar 31, 2019287-10.6%Form 10-Q (filed 2020-05-08) ↗
Q4 2018Dec 31, 2018264-6.4%Form 10-K (filed 2020-02-21) ↗
Q3 2018Sep 30, 201897-16.4%Form 10-Q (filed 2019-11-06) ↗
Q2 2018Jun 30, 201844+10.0%Form 10-Q (filed 2019-08-05) ↗
Q1 2018Mar 31, 2018321+7.0%Form 10-Q (filed 2019-05-03) ↗
Q4 2017Dec 31, 2017282–Form 10-K (filed 2020-02-21) ↗
Q3 2017Sep 30, 2017116–Form 10-Q (filed 2018-11-07) ↗
Q2 2017Jun 30, 201740–Form 10-Q (filed 2018-08-07) ↗
Q1 2017Mar 31, 2017300–Form 10-Q (filed 2018-05-04) ↗

Cite this data

StockData. (2026). AbbVie Synagis (palivizumab) — International net revenues [legacy through FY20Q1] ($M) ($M), quarterly Q1 2017–Q1 2020 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/synagis_intl

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.